Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Citius Pharmaceuticals stock

Learn how to easily invest in Citius Pharmaceuticals stock.

Citius Pharmaceuticals Inc is a biotechnology business based in the US. Citius Pharmaceuticals shares (CTXR) are listed on the NASDAQ and all prices are listed in US Dollars. Citius Pharmaceuticals employs 15 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Citius Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CTXR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Citius Pharmaceuticals stock price (NASDAQ: CTXR)

Use our graph to track the performance of CTXR stocks over time.

Citius Pharmaceuticals shares at a glance

Information last updated 2022-06-24.
Latest market close$0.98
52-week range$0.83 - $3.85
50-day moving average $1.03
200-day moving average $1.56
Wall St. target price$6.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.20

Buy Citius Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Citius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Citius Pharmaceuticals price performance over time

Historical closes compared with the close of $0.977 from 2022-06-24

1 week (2022-06-17) 10.88%
1 month (2022-05-23) N/A
3 months (2022-03-24) -48.31%
6 months (2021-12-23) N/A
1 year (2021-06-25) -74.42%
2 years (2020-06-26) -29.20%
3 years (2019-06-27) 4.92%
5 years (2017-06-26) 6.22

Citius Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -13.35%
Return on equity TTM -22.6%
Profit margin 0%
Book value $0.81
Market capitalisation $142.7 million

TTM: trailing 12 months

Citius Pharmaceuticals share dividends

We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.

Have Citius Pharmaceuticals's shares ever split?

Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.

Citius Pharmaceuticals share price volatility

Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.831 up to $3.85. A popular way to gauge a stock's volatility is its "beta".

CTXR.US volatility(beta: 1.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.6484. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Citius Pharmaceuticals overview

Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. .

Frequently asked questions

What percentage of Citius Pharmaceuticals is owned by insiders or institutions?
Currently 8.423% of Citius Pharmaceuticals shares are held by insiders and 18.434% by institutions.
How many people work for Citius Pharmaceuticals?
Latest data suggests 15 work at Citius Pharmaceuticals.
When does the fiscal year end for Citius Pharmaceuticals?
Citius Pharmaceuticals's fiscal year ends in September.
Where is Citius Pharmaceuticals based?
Citius Pharmaceuticals's address is: 11 Commerce Drive, Cranford, NJ, United States, 07016
What is Citius Pharmaceuticals's ISIN number?
Citius Pharmaceuticals's international securities identification number is: US17322U2078
What is Citius Pharmaceuticals's CUSIP number?
Citius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 17322U207

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site